Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in traditional channels.
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free for over three years of using the drug, according to new data from the drugmaker Eli Lilly.
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease,
Novo Nordisk readies trial results for next-generation weight-loss drug
The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...
The UK thinks weight loss drugs could ease unemployment. Experts say that’s a fantasy
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
tyla5d
Company behind weight loss drug Mounjaro issues statement as first Brit dies after using jab twice
Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...
5 new weight-loss drugs to watch in the fight for the next Ozempic
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Woman Dies After Using Weight-Loss Drug In U.K.’s First Case
A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...